PGEN — PRECIGEN, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1356090 ·
Last close
$7.17
Market Cap
$2.56B
52W High
$7.50
52W Low
$3.51
ADV30
5,267,471
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 54,978,000 | 52,173,000 | 22,642,000 | 20,071,000 | 170,296,000 | 16,329,000 | 126,720,000 |
| Mar 2026 | 23,252,000 | 20,693,000 | -5,994,000 | -7,929,000 | 138,627,000 | 7,480,000 | 118,392,000 |
| Dec 2025 | 4,565,000 | 2,969,000 | -21,666,000 | -23,503,000 | 155,505,000 | 30,234,000 | 134,594,000 |
| Sep 2025 | 2,922,000 | 1,887,000 | -34,481,000 | -146,344,000 | 171,264,000 | 14,322,000 | 129,396,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-114,165,000
Investing CF
$24,137,000
Financing CF
$92,569,000
CapEx
$-1,057,000
Dividends Paid
—
Buybacks
$-1,841,000
EPS Diluted TTM
$-1.12
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,329,206,000
Inventory
$20,245,000
Receivables
$72,044,000
ST Investments
$21,879,000
EBIT TTM
$-147,978,000
Pretax Income TTM
$-157,705,000
Interest Exp TTM
$9,727,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$85,717,000
EBITDA
$-35,359,000
Free Cash Flow
$-100,097,248
Enterprise Value
$2,627,249,664
Total Cash
$38,208,000
Total Debt
$98,345,000
Shares Out
356,510,980
Trailing EPS
$-1.07
Book Value
$0.12
ROE
-837.1%
ROA
-18.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,684,000 | -106,600,000 | -250,642,000 | 155,505,000 | 134,594,000 | — | -87,831,000 |
| Dec 2024 | 3,925,000 | -94,705,000 | -126,235,000 | 145,266,000 | 106,753,000 | — | -68,173,000 |
| Dec 2023 | 6,225,000 | -88,923,000 | -95,904,000 | 151,043,000 | 32,545,000 | — | -66,930,000 |
| Dec 2022 | 26,909,000 | -74,606,000 | 28,317,000 | 215,977,000 | 89,718,000 | — | -65,045,000 |
TTM Snapshot
Revenues TTM
$3,333,000
NetIncome TTM
$13,842,000
OpCashFlow TTM
$0
Assets (Latest)
$145,266,000
Forward EPS
$-0.22
Max Pain — expiry 2026-09-18
max pain strike: $5.00 · spot: $7.37 · call oi: 25,491 · put oi: 337
Expected Move to 2026-09-18:
±$0.88
(11.87%) —
implied range
$6.49 –
$8.24
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | $2.58B | $18.08 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.54B | $25.72 | — |
| NKTR | NEKTAR THERAPEUTICS | $2.52B | $73.69 | — |
| BHC | Bausch Health Companies Inc. | $2.50B | $6.68 | — |
| PHVS | Pharvaris N.V. | $2.62B | $37.31 | — |
News headlines (Yahoo Finance, 1h cache)
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers
2026-08-25 11:00 · Yahoo
Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice
2026-08-14 16:00 · Yahoo
Can Precigen (PGEN) Justify Its Valuation On Earnings And PAPZIMEOS Launch?
2026-08-12 18:12 · Yahoo
Precigen (PGEN) Q2 2026 Earnings Call Transcript
2026-08-12 00:30 · Yahoo
Precigen Inc (PGEN) (Q2 2026) Earnings Call Highlights: Revenue Surges 145% and Net Profit Achieved
2026-08-05 05:04 · Yahoo
Precigen Q2 Earnings Call Highlights
2026-08-05 02:03 · Yahoo
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
2026-08-04 20:01 · Yahoo
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
2026-07-21 12:00 · Yahoo
What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?
2026-07-15 22:29 · Yahoo
Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason
2026-06-23 01:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.